EFG Asset Management North America Corp. Sells 163 Shares of IQVIA Holdings Inc. (NYSE:IQV)

EFG Asset Management North America Corp. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 13,736 shares of the medical research company’s stock after selling 163 shares during the period. EFG Asset Management North America Corp.’s holdings in IQVIA were worth $2,701,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Avior Wealth Management LLC grew its holdings in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares in the last quarter. Synergy Asset Management LLC purchased a new position in shares of IQVIA in the fourth quarter worth about $33,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA in the fourth quarter valued at approximately $44,000. Versant Capital Management Inc lifted its stake in shares of IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after buying an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in IQVIA in the 4th quarter worth approximately $60,000. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of several recent research reports. JPMorgan Chase & Co. dropped their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Morgan Stanley raised their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Trading Down 2.7 %

NYSE IQV opened at $181.07 on Wednesday. The stock has a 50-day moving average of $194.24 and a 200-day moving average of $207.29. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $253.84. The firm has a market cap of $31.93 billion, a PE ratio of 24.14, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.